ANAlexandra A. C. Newman

Alexandra A. C. Newman

*This is an algorithmically generated author record based on publicly available information.

Alexandra A. C. Newman has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Kathryn J. Moore

    Leon H. Charney Division of Cardiology, Department of Medicine NYU Grossman School of Medicine New York New York USA

    6 shared publications
  • Coen van Solingen

    Cardiovascular Research Center, Department of Medicine, New York University Grossman School of Medicine, New York, USA

    5 shared publications
  • Gary K. Owens

    Robert M. Berne Cardiovascular Research Center (R.A.D., T.R., V.M.M., L.S.S., A.M.C., A.S., S.B., G.K.O.), University of Virginia School of Medicine, Charlottesville

    4 shared publications
  • Martin Schlegel

    Department of Anesthesiology and Intensive Care Medicine, Technical University of Munich, Klinikum rechts der Isar, Technical University of Munich (TUM) School of Medicine and Health, Munich 81675, Germany

    3 shared publications
  • Monika Sharma

    Department of Medicine, Cardiovascular Research Center, New York University Grossman School of Medicine, New York, NY 10016

    3 shared publications
  • Edward A. Fisher

    Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, USA

    2 shared publications

Latest Publications

  • Open Access

    Ischemic Injury Drives Tumor Growth via Accelerated Hematopoietic Aging

    by Alexandra A. C. Newman, José Gabriel Barcia Durán, Richard Von Itter, Jessie M. Dalman, Brian Lim, Morgane Gourvest, Tarik Zahr, Kristin M. Wang, Tracy Zhang, Noah Albarracin, et al.

    Background: Patients with peripheral artery disease have increased risk of cancer development. Aging-associated changes in hematopoietic stem and progenitor cells (HSPCs), including inflammation and increased myelopoiesis, are implicated in both cardiovascular disease (CVD) and cancer, but their contributions to CVD-driven tumor progression are unclear. Objectives: To study cancer growth following peripheral ischemia and consequent changes within the HSPC bone marrow compartment to uncover mechanisms through which altered hematopoiesis promotes oncogenesis. Methods: Mammary cancer cell (E0771) growth was monitored in C57BL/6J mice after hind limb ischemia (HLI) or sham surgery. The tumor immune microenvironment, circulatory immune cells, and HSPC compartment were assessed by flow cytometry. Next-generation single-cell RNA and ATAC sequencing of HSPCs was performed to assess transcriptomic and epigenetic changes. The functional impact on tumor progression and persistence of ischemia-induced epigenetic reprogramming of HSPCs and their myeloid progeny was examined by bone marrow transplantation. Results: Peripheral ischemia increased monocyte and neutrophil output at the expense of lymphocytes, driven by a shift toward CD150 hi myeloid-biased hematopoietic stem cells (HSCs). This was associated with accelerated breast cancer growth and increased accumulation of tumoral immunosuppressive regulatory T cells and monocytes. Increased myelopoiesis was also supported by multiomic analyses showing HLI-induced transcriptional and epigenetic enrichment for inflammatory (NLRP3 inflammasome) and aging-associated (Neogenin-1, Thrombospondin-1) signatures in subsets of monocyte/dendritic progenitors. HLI-accelerated tumor growth and myeloid-skewing was transmissible via bone marrow transplantation, indicating long-term reprogramming of innate immune responses. Conclusions: Peripheral ischemia promotes inflammaging of HSCs and long-lasting alterations to anti-tumoral immunity, accelerating breast tumor growth.

  • Cardiovascular Disease and Cancer: A Dangerous Liaison

    by Alexandra A.C. Newman, Jessie M. Dalman, Kathryn J. Moore

    The field of cardio-oncology has traditionally focused on the impact of cancer and its therapies on cardiovascular health. Mounting clinical and preclinical evidence, however, indicates that the reverse may also be true: cardiovascular disease can itself influence tumor growth and metastasis. Numerous epidemiological studies have reported that individuals with prevalent cardiovascular disease have an increased incidence of cancer. In parallel, studies using preclinical mouse models of myocardial infarction, heart failure, and cardiac remodeling support the notion that cardiovascular disorders accelerate the growth of solid tumors and metastases. These findings have ushered in a new and burgeoning field termed reverse cardio-oncology that investigates the impact of cardiovascular disease pathophysiology on cancer emergence and progression. Recent studies have begun to illuminate the mechanisms driving this relationship, including shared risk factors, reprogramming of immune responses, changes in gene expression, and the release of cardiac factors that result in selective advantages for tumor cells or their local milieu, thus exacerbating cancer pathology. Here, we review the evidence supporting the relationship between cardiovascular disease and cancer, the mechanistic pathways enabling this connection, and the implications of these findings for patient care.


  • Open Access

    lncRNACARINHregulates expression and function of innate immune transcription factor IRF1 in macrophages

    by Yannick Cyr, Morgane Gourvest, Grace O Ciabattoni, Tracy Zhang, Alexandra Ac Newman, Tarik Zahr, Sofie Delbare, Florencia Schlamp, Meike Dittmann, Kathryn J Moore, et al.

    The discovery of long non-coding RNAs (lncRNAs) has provided a new perspective on the centrality of RNA in gene regulation and genome organization. Here, we screened for lncRNAs with putative functions in the host response to single-stranded RNA respiratory viruses. We identifyCARINHas a conserved cis-acting lncRNA up-regulated in three respiratory diseases to control the expression of its antisense geneIRF1, a key transcriptional regulator of the antiviral response.CARINHandIRF1are coordinately increased in the circulation of patients infected with human metapneumovirus, influenza A virus, or SARS-CoV-2, and in macrophages in response to viral infection or TLR3 agonist treatment. Targeted depletion ofCARINHor its mouse orthologCarinhin macrophages reduces the expression of IRF1/Irf1 and their associated target gene networks, increasing susceptibility to viral infection. Accordingly, CRISPR-mediated deletion ofCarinhin mice reduces antiviral immunity, increasing viral burden upon sublethal challenge with influenza A virus. Together, these findings identify a conserved role of lncRNACARINHin coordinating interferon-stimulated genes and antiviral immune responses.


  • Open Access

    Targeting Unc5b in macrophages drives atherosclerosis regression and pro-resolving immune cell function

    by Martin Schlegel, Yannick Cyr, Alexandra A. C. Newman, Korbinian Schreyer, José Gabriel Barcia Durán, Monika Sharma, Fazli K. Bozal, Morgane Gourvest, Maxwell La Forest, Milessa S. Afonso, et al.

    Atherosclerosis results from lipid-driven inflammation of the arterial wall that fails to resolve. Imbalances in macrophage accumulation and function, including diminished migratory capacity and defective efferocytosis, fuel maladaptive inflammation and plaque progression. The neuroimmune guidance cue netrin-1 has dichotomous roles in inflammation partly due to its multiple receptors; in atherosclerosis, netrin-1 promotes macrophage survival and retention via its receptor Unc5b. To minimize the pleiotropic effects of targeting netrin-1, we tested the therapeutic potential of deleting Unc5b in mice with advanced atherosclerosis. We generated Unc5b fl/fl Cx3cr1 creERT2/WT mice, which allowed conditional deletion of Un5b (∆ Unc5b MØ ) in monocytes and macrophages by tamoxifen injection. After inducing advanced atherosclerosis by hepatic PCSK9 overexpression and western diet feeding for 20 wk, Unc5b was deleted and hypercholesterolemia was normalized to simulate clinical lipid management. Deletion of myeloid Unc5b led to a 40% decrease in atherosclerotic plaque burden and reduced plaque complexity compared to Unc5b fl/fl Cx3cr1 WT/WT littermate controls (Ctrl MØ ). Consistently, plaque macrophage content was reduced by 50% in ∆ Unc5b MØ mice due to reduced plaque Ly6C hi monocyte recruitment and macrophage retention. Compared to Ctrl MØ mice, plaques in ∆ Unc5b MØ mice had reduced necrotic area and fewer apoptotic cells, which correlated with improved efferocytotic capacity by Unc5b -deficient macrophages in vivo and in vitro. Beneficial changes in macrophage dynamics in the plaque upon Unc5b deletion were accompanied by an increase in atheroprotective T cell populations, including T-regulatory and Th2 cells. Our data identify Unc5b in advanced atherosclerosis as a therapeutic target to induce pro-resolving restructuring of the plaque immune cells and to promote atherosclerosis regression.


  • Extracellular Vesicles: Bridging the Heart and Tumor in Reverse Cardio-Oncology

    by Alexandra A.C. Newman, Richard Von Itter, Kathryn J. Moore


  • Open Access

    SMC-Derived Hyaluronan Modulates Vascular SMC Phenotype in Murine Atherosclerosis

    by Felicia Hartmann, Daniel J. Gorski, Alexandra A.C. Newman, Susanne Homann, Anne Petz, Katherine M. Owsiany, Vlad Serbulea, Yu-Qing Zhou, Rebecca A. Deaton, Michelle Bendeck, et al.

    Rationale: Plaque instability remains poorly understood and new therapeutic approaches to reduce plaque rupture and subsequent clinical events are of great interest. Recent studies revealed an important role of phenotypic switching of smooth muscle cells (SMC) in controlling plaque stability, including ECM (extracellular matrix) deposition. Objective: The aim of this study was to elucidate the role of hyaluronan derived from SMC–hyaluronan synthase 3 ( Has3 ), in phenotypic switching and plaque stability in an animal model of atherosclerosis. Methods and Results: A mouse line with SMC-specific deletion of Has3 and simultaneous SMC-lineage tracing ( e YFP [enhanced yellow fluorescent protein]) on an Apoe −/− background was used. Lineage tracing of SMC with e YFP revealed that SMC-specific deletion of Has3 significantly increased the number of LGALS3 + (galectin-3) transition state SMC and decreased ACTA2 + (alpha-smooth muscle actin) SMC. Notably, SMC- Has3 deletion led to significantly increased collagen deposition and maturation within the fibrous cap and the whole lesion, as evidenced by picrosirius red staining and LC-PolScope analysis. Single-cell RNA sequencing of brachiocephalic artery lesions demonstrated that the loss of SMC- Has3 enhanced the transition of SMC to a Lgals3 + , ECM-producing phenotype with elevated acute-phase response gene expression. Experiments using cultured murine aortic SMC revealed that blocking CD44 (cluster of differentiation-44), an important hyaluronan binding receptor, recapitulated the enhanced acute-phase response, and synthesis of fibrous ECM. Conclusions: These studies provide evidence that the deletion of SMC- Has3 results in an ECM-producing transition state SMC phenotype (characterized by LGALS3 + expression), likely via reduced CD44 signaling, resulting in increased collagen formation and maturation, an index consistent with increased plaque stability.


  • Silencing Myeloid Netrin-1 Induces Inflammation Resolution and Plaque Regression

    by Martin Schlegel, Monika Sharma, Emily J. Brown, Alexandra A.C. Newman, Yannick Cyr, Milessa Silva Afonso, Emma M. Corr, Graeme J. Koelwyn, Coen van Solingen, Jonathan Guzman, et al.

    Rationale: Therapeutic efforts to decrease atherosclerotic cardiovascular disease risk have focused largely on reducing atherogenic lipoproteins, yet lipid-lowering therapies alone are insufficient to fully regress plaque burden. We postulate that arterial repair requires resolution of a maladaptive immune response and that targeting factors that hinder inflammation resolution will facilitate plaque regression. Objective: The guidance molecule Ntn1 (netrin-1) is secreted by macrophages in atherosclerotic plaques, where it sustains inflammation by enhancing macrophage survival and blocking macrophage emigration. We tested whether silencing Ntn1 in advanced atherosclerosis could resolve arterial inflammation and regress plaques. Methods and Results: To temporally silence Ntn1 in myeloid cells, we generated genetically modified mice in which Ntn1 could be selectively deleted in monocytes and macrophages using a tamoxifen-induced CX3CR1-driven cre recombinase ( Ntn1 fl/fl Cx3cr1 creERT2+ ) and littermate control mice ( Ntn1 fl/fl Cx3cr1 WT ). Mice were fed Western diet in the setting of hepatic PCSK9 (proprotein convertase subtilisin/kexin type 9) overexpression to render them atherosclerotic and then treated with tamoxifen to initiate deletion of myeloid Ntn1 (Mø ΔNtn1 ) or not in controls (Mø WT ). Morphometric analyses performed 4 weeks later showed that myeloid Ntn1 silencing reduced plaque burden in the aorta (−50%) and plaque complexity in the aortic root. Monocyte-macrophage tracing experiments revealed lower monocyte recruitment, macrophage retention, and proliferation in Mø ΔNtn1 compared with Mø WT plaques, indicating a restructuring of monocyte-macrophage dynamics in the artery wall upon Ntn1 silencing. Single-cell RNA sequencing of aortic immune cells before and after Ntn1 silencing revealed upregulation of gene pathways involved in macrophage phagocytosis and migration, including the Ccr7 chemokine receptor signaling pathway required for macrophage emigration from plaques and atherosclerosis regression. Additionally, plaques from Mø ΔNtn1 mice showed hallmarks of inflammation resolution, including higher levels of proresolving macrophages, IL (interleukin)-10, and efferocytosis, as compared to plaques from Mø WT mice. Conclusion: Our data show that targeting Ntn1 in advanced atherosclerosis ameliorates atherosclerotic inflammation and promotes plaque regression.


  • Top Cited Papers

    Multiple cell types contribute to the atherosclerotic lesion fibrous cap by PDGFRβ and bioenergetic mechanisms

    by Alexandra A. C. Newman, Vlad Serbulea, Richard A. Baylis, Laura S. Shankman, Xenia Bradley, Gabriel F. Alencar, Katherine Owsiany, Rebecca A. Deaton, Santosh Karnewar, Sohel Shamsuzzaman, et al.

    Stable atherosclerotic plaques are characterized by a thick, extracellular matrix-rich fibrous cap populated by protective ACTA2+ myofibroblast (MF)-like cells, assumed to be almost exclusively derived from smooth muscle cells (SMCs). Herein, we show that in murine and human lesions, 20% to 40% of ACTA2+ fibrous cap cells, respectively, are derived from non-SMC sources, including endothelial cells (ECs) or macrophages that have undergone an endothelial-to-mesenchymal transition (EndoMT) or a macrophage-to-mesenchymal transition (MMT). In addition, we show that SMC-specific knockout of the Pdgfrb gene, which encodes platelet-derived growth factor receptor beta (PDGFRβ), in Apoe−/− mice fed a Western diet for 18 weeks resulted in brachiocephalic artery lesions nearly devoid of SMCs but with no changes in lesion size, remodelling or indices of stability, including the percentage of ACTA2+ fibrous cap cells. However, prolonged Western diet feeding of SMC Pdgfrb-knockout mice resulted in reduced indices of stability, indicating that EndoMT- and MMT-derived MFs cannot compensate indefinitely for loss of SMC-derived MFs. Using single-cell and bulk RNA-sequencing analyses of the brachiocephalic artery region and in vitro models, we provide evidence that SMC-to-MF transitions are induced by PDGF and transforming growth factor-β and dependent on aerobic glycolysis, while EndoMT is induced by interleukin-1β and transforming growth factor-β. Together, we provide evidence that the ACTA2+ fibrous cap originates from a tapestry of cell types, which transition to an MF-like state through distinct signalling pathways that are either dependent on or associated with extensive metabolic reprogramming.


  • Top Cited Papers

    Myocardial infarction accelerates breast cancer via innate immune reprogramming

    by Graeme J. Koelwyn, Alexandra A. C. Newman, Milessa S. Afonso, Coen van Solingen, Emma M. Corr, Emily J. Brown, Kathleen B. Albers, Naoko Yamaguchi, Deven Narke, Martin Schlegel, et al.

    Disruption of systemic homeostasis by either chronic or acute stressors, such as obesity1 or surgery2, alters cancer pathogenesis. Patients with cancer, particularly those with breast cancer, can be at increased risk of cardiovascular disease due to treatment toxicity and changes in lifestyle behaviors3,4,5. While elevated risk and incidence of cardiovascular events in breast cancer is well established, whether such events impact cancer pathogenesis is not known. Here we show that myocardial infarction (MI) accelerates breast cancer outgrowth and cancer-specific mortality in mice and humans. In mouse models of breast cancer, MI epigenetically reprogrammed Ly6Chi monocytes in the bone marrow reservoir to an immunosuppressive phenotype that was maintained at the transcriptional level in monocytes in both the circulation and tumor. In parallel, MI increased circulating Ly6Chi monocyte levels and recruitment to tumors and depletion of these cells abrogated MI-induced tumor growth. Furthermore, patients with early-stage breast cancer who experienced cardiovascular events after cancer diagnosis had increased risk of recurrence and cancer-specific death. These preclinical and clinical results demonstrate that MI induces alterations in systemic homeostasis, triggering cross-disease communication that accelerates breast cancer.


  • Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade

    by Ying Wang, Vivek Nanda, Daniel Direnzo, Jianqin Ye, Sophia Xiao, Yoko Kojima, Kathryn L. Howe, Kai-Uwe Jarr, Alyssa M. Flores, Pavlos Tsantilas, et al.

    Significance: Cardiovascular disease remains the world’s leading killer, despite the widespread use of cholesterol-lowering medicines. Recent studies suggest a portion of this residual risk may result from the clonal expansion of cells within the atherosclerotic plaques of diseased blood vessels. How these cells promote inflammation and whether they can be therapeutically targeted remain unclear. The current study suggests that clonally expanding cells may cause disease by triggering the complement cascade while evading immune surveillance. However, these cells also appear to be susceptible to therapies that reactivate phagocytic clearance pathways, suggesting a potential treatment approach for heart disease similar to current oncology efforts directed against the cancer stem cell.